Search clinical trials for: Serine Proteinase Inhibitors

Total 71786 results

Sagent Pharmaceuticals Inc.

Completed

Camostat Efficacy vs. Placebo for Outpatient Treatment of COVID-19 (CAMELOT)

COVID-19

United States
Pirogov Russian National Research Medical University

Completed

Rivaroxaban With Diosmin in Long-term Treatment of Deep Vein Thrombosis (RIDILOTT-DVT)

Deep Vein Thrombosis | Postthrombotic Syndrome

Russian Federation
Electrophysiology Research Foundation
Axio Research Corporation

Terminated

EdoxabaN or Warfarin Therapy In Device Procedures in Patients With Non-Valvular Atrial Fibrillation (ENTICED-AF)

Atrial Fibrillation

United States
Zagazig University

Completed

Efficacy and Safety of Rivaroxaban in Acute Non-neoplastic Portal Vein Thrombosis in HCV

Portal Vein Thrombosis
Bristol-Myers Squibb
Pfizer

Completed

Phase 1 Bioavailability Study of Apixaban Solution Formulation Relative to Apixaban Tablets in Healthy Subjects

Healthy Volunteers

United States
GlaxoSmithKline

Completed

ARIXTRA® Adherence in SVT Patients.

Thrombosis, Venous
Shanghai Tong Ren Hospital

Recruiting

Impact of Early PCSK9 Inhibitor on Heart After Acute Myocardium Infarction (PERFECT-AMI)

Early PCSK9 Inhibitor on Ventricular Remodling

China
Ottawa Hospital Research Institute
Canadian Institutes of Health Research (CIHR); Canadian Venous Thromboembolism... and other collaborators

Not yet recruiting

VTE Prevention With Rivaroxaban in Genitourinary Cancer Patients Receiving Systemic Therapy (PREVENT-GU)

Venous Thromboembolism | Urologic Cancer
Brigham and Women's Hospital

Recruiting

The Impact of Pcsk-9 Inhibition on PET CFR in Patients at High CV Risk (EMPOWER)

Stable Coronary Disease

United States
Mitsubishi Tanabe Pharma GmbH

Completed

Safety of Argatroban Infusion in Conduction Disturbances (SAICoDis)

Stable Coronary Artery Disease (CAD) | Unstable Angina (Troponin Negative)

Germany
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Active, not recruiting

Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Deep Vein Thrombosis | Pulmonary Embolism | Metastatic Malignant Solid Neoplasm | Cerebral Vein Thrombosis | Splanchnic Vein Thrombosis

United States
Bayer

Completed

A Study to Learn Whether There Are Differences in the Kidney's Ability to Work Properly in Korean Patients With Non-valvular Atrial Fibrillation (Irregular and Often Rapid Heartbeat Not Caused by a Heart Valve Problem) Treated With Rivaroxaban as Compared to Those Treated With Warfarin (RENOVATOR)

Non-valvular Atrial Fibrillation (NVAF)

Korea, Republic of
Second Affiliated Hospital, School of Medicine,...

Completed

Efficacy Argatroban in Ischemic Stroke With Early Deterioration (EASE) (EASE)

Acute Progressive Ischemic Stroke

China
Portola Pharmaceuticals

Completed

Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 2 of 4)

Healthy Volunteers
Portola Pharmaceuticals

Completed

Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 4 of 4)

Healthy Volunteers
Fujita Health University

Completed

Rivaroxaban Estimation With Warfarin in Atrial Fibrillation Patients With Coronary Stent Implantation Study (REWRAPS) (REWRAPS)

Coronary Artery Disease | Stroke | Atrial Fibrillation | All Cause Mortality | Fetal Blood Loss | Major Bleeding

Japan
McMaster University

Completed

Improved Adherence With Extended Venous Thromboembolism Prophylaxis After Major Cancer Surgery

Surgery | Venous Thromboembolism | Adherence, Medication | Prophylaxis | Neoplasms Malignant

Canada
General Hospital of Shenyang Military Region

Completed

Argatroban Plus R-tPA for Acute Ischemic Stroke

Stroke

China
Perosphere Pharmaceuticals Inc, a wholly owned...

Completed

Phase 2 Study of Rivaroxaban Reversal by Ciraparantag as Measured by WBCT

Healthy

United States
Pfizer

Completed

Study of PF-04965842 Effect on Dabigatran Pharmacokinetics in Healthy Participants

Healthy

Belgium
GlaxoSmithKline

Completed

Total Hip Replacement Study Of GSK576428 (Fondaparinux Sodium)

Thrombosis, Venous
Hamilton Health Sciences Corporation
Population Health Research Institute

Unknown

Apixaban Dose Reduction in Patients With Elevated Drug Levels (ADREL)

Atrial Fibrillation

Canada
University of Michigan

Withdrawn

Evaluation of Wound Drainage After Knee or Hip Arthroplasty

Complications; Arthroplasty

United States
Bayer

Terminated

Study to Investigate the Effect of Aprotinin of Transfusion Requirements in Patients Undergoing Surgical Procedures for Lung or Esophageal Cancer

Blood Loss, Surgical

United States, Australia, Austria, Belgium, Canada, Denmark, France, Germany, Spain, United Kingdom
Bayer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension Study

Venous Thromboembolism

United Kingdom, Belgium, France, Israel, Italy, Spain, China, Hong Kong, Korea, Republic of, New Zealand, Poland, India, United States, Hungary, Singapore, Canada, Australia, Netherlands, Austria, Switzerland, Taiwan, Brazil, Denmark, German... and more
Brigham and Women's Hospital
GlaxoSmithKline

Completed

Fondaparinux as Monotherapy for DVT and/or Pulmonary Embolism

Deep Vein Thrombosis | Pulmonary Embolism

United States
Kamada, Ltd.

Completed

Phase II Study of the Safety and Efficacy of Inhaled Alpha-1 Antitrypsin (AAT ) in Cystic Fibrosis Patients

Cystic Fibrosis

Israel
Vanderbilt University Medical Center

Terminated

Blood Pressure Lowering Effects of Angiotensin-(1-7) in Primary Autonomic Failure

Shy-Drager Syndrome | Pure Autonomic Failure | Orthostatic Hypotension, Dysautonomic | Autonomic Nervous System Disorders

United States
China National Center for Cardiovascular Diseases

Not yet recruiting

Low-dose Versus Standard-dose Rivaroxaban in Elderly Patients With Atrial Fibrillation

Stroke | Atrial Fibrillation | Major Adverse Cardiac Events | Anticoagulant Adverse Reaction
University of Pennsylvania
National Heart, Lung, and Blood Institute (NHLBI); Amgen

Not yet recruiting

Mechanistic Clinical Trial of PCSK9 Inhibition for AAA

Abdominal Aortic Aneurysm
Kevin H.M. Kuo, MD, MSc, FRCPC

Recruiting

THromboprophylaxis In Sickle Cell Disease With Central Venous Catheters (THIS) (THIS)

Sickle Cell Disease | Venous Thromboembolism | Central Venous Catheter Thrombosis

Canada
University of Texas at Austin
University of Kansas

Not yet recruiting

Restart TICrH Alpha Pilot Protocol, Restarting DOACs After Traumatic Intracranial Hemorrhage

Anticoagulants; Increased
McMaster University

Recruiting

Postoperative Extended Venous Thromboprophylaxis in Inflammatory Bowel Disease (EXPAND)

Crohn Disease | Ulcerative Colitis | Venous Thromboembolism | Colorectal Disorders | Pulmonary Embolism | IBD

Canada
Brigham and Women's Hospital

Active, not recruiting

Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in High-Risk Patients With Provoked Venous Thromboembolism (HI-PRO)

Deep Vein Thrombosis | Venous Thromboembolism | Pulmonary Embolism

United States
Montreal Heart Institute
Servier

Active, not recruiting

Canadian EdoxAban(Lixiana®) Registry in Patients With ATrial Fibrillation/Flutter With Confirmed ValvUlar HeaRt DiseasE (CAPTURE)

Valvular Heart Disease | Atrial Fibrillation and Flutter

Canada
Inova Health Care Services

Terminated

Antiplatelet Effects of Evolocumab in Patients With Peripheral Arterial Disease

Peripheral Arterial Disease

United States
Bristol-Myers Squibb

Completed

Real-World Comparative Observational Study in Non-Valvular Atrial Fibrillation Patients Using Oral Anticoagulants

Atrial Fibrillation
Grifols Therapeutics LLC
Grifols Japan K.K.

Completed

Safety and Pharmacokinetics of Alpha-1 MP (Alpha1-proteinase Inhibitor (Human), Modified Process) in Participants With Alpha1-Antitrypsin Deficiency

Alpha1-Antitrypsin Deficiency

Japan
AIO-Studien-gGmbH
Bayer; Charite University, Berlin, Germany

Terminated

Rivaroxaban in the Treatment of Venous Thromboembolism (VTE) in Cancer Patients

Cancer | Venous Thromboembolism

Germany
Perosphere Pharmaceuticals Inc, a wholly owned...

Completed

Phase 2 Study of Apixaban Reversal by Ciraparantag as Measured by WBCT

Healthy

United States
Bayer

Terminated

Effect of Aprotinin on Transfusion Requirements in Patients Undergoing Elective Spinal Fusion Surgery

Blood Loss, Surgical | Postoperative Hemorrhage

Spain, Germany, Canada
Bristol-Myers Squibb
Pfizer

Completed

Phase 1 Oral Solution and Crushed Tablet Relative Bioavailability Study of Apixaban When Administered Through a Nasogastric Tube in Healthy Subjects

Healthy Subjects

United States
Boehringer Ingelheim

Completed

Study to Investigate the Pharmacokinetics (PK) and Pharmacodynamics (PD) of Idarucizumab in Chinese Healthy Male and Female Volunteers Who Had Taken Dabigatran Etexilate and Whose Plasma Concentrations of Dabigatran Were at or Close to Steady State

Healthy Volunteers

China
Boehringer Ingelheim

Completed

Safety, Pharmacokinetics and Pharmacodynamics After Single Rising Oral Doses of BIBR 1048 MS as Capsules in Healthy Subjects of Japanese and Caucasian Origin

Healthy
NYU Langone Health
Guerbet

Completed

Effects Contrast on Platelet Activity, Thrombosis and Fibrinolysis in Patients Undergoing Coronary Angiography

Coronary Artery Disease

United States
Boehringer Ingelheim

Completed

Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BI 655075 (Idarucizumab) Administered Alone or With Dabigatran Etexilate in Japanese Healthy Subjects

Healthy

Japan
Boehringer Ingelheim

Completed

Bioequivalence of Two Different Generations of Drug Product of Dabigatran Etexilate Following Oral Administration in Healthy Male and Female Volunteers

Healthy
AstraZeneca

Terminated

Melagatran/Ximelagatran Versus Enoxaparin for the Prevention of Venous Thromboembolic Events (EXTEND)

Thromboembolism

Sweden, France, Mexico, Poland, South Africa, Spain, Germany, Hungary, Denmark, Finland, Netherlands, Norway, Austria, Belgium, Portugal, Switzerland
Lin Zhao

Recruiting

Effect of Evolocumab on Chronic Total Occlusions (EVOLO-CTO)

In-stent Restenosis | Major Adverse Cardiovascular Events

China
Basma Rabiey

Not yet recruiting

Comparison Between Haparin and Herodin in HD

Haemodialysis

Search clinical trials for: Serine Proteinase Inhibitors

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Philippines

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations